MAGENTA THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.5 USD | +2.43% |
|
-7.53% | +92.07% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Capitalization 1 | 188.7 | 584.6 | 376.7 | 258.2 | 23.75 |
| Enterprise Value (EV) 1 | 46.11 | 438.9 | 227.9 | 81.25 | -58.32 |
| P/E ratio | -1.82 x | -7.31 x | -4.6 x | -3.42 x | -0.31 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -0.78 x | -5.41 x | -2.97 x | -1.12 x | 0.74 x |
| EV / FCF | -1.59 x | -10.8 x | -5.85 x | -2.18 x | 1.39 x |
| FCF Yield | -62.8% | -9.28% | -17.1% | -45.9% | 71.8% |
| Price to Book | 1.3 x | 4.22 x | 2.64 x | 1.5 x | 0.22 x |
| Nbr of stocks (in thousands) | 2,069 | 2,410 | 3,003 | 3,642 | 3,759 |
| Reference price 2 | 91.20 | 242.6 | 125.4 | 70.88 | 6.320 |
| Announcement Date | 3/19/19 | 3/3/20 | 3/3/21 | 3/8/22 | 3/23/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -35.35 | -59.09 | -81.13 | -76.72 | -72.67 | -78.98 |
| EBIT 1 | -35.73 | -59.96 | -82.97 | -78.7 | -74.69 | -80.9 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -35.49 | -57.52 | -76.77 | -74.94 | -71.14 | -76.46 |
| Net income 1 | -35.49 | -57.52 | -76.77 | -74.94 | -71.14 | -76.46 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -305.9 | -50.12 | -33.18 | -27.30 | -20.71 | -20.61 |
| Free Cash Flow 1 | -14.83 | -28.94 | -40.74 | -38.93 | -37.26 | -41.86 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/24/18 | 3/19/19 | 3/3/20 | 3/3/21 | 3/8/22 | 3/23/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 51.4 | 143 | 146 | 149 | 177 | 82.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -14.8 | -28.9 | -40.7 | -38.9 | -37.3 | -41.9 |
| ROE (net income / shareholders' equity) | -120% | -58.7% | -53.5% | -52.6% | -44.9% | -54.9% |
| ROA (Net income/ Total Assets) | -67.9% | -35.4% | -32.5% | -30.4% | -26.6% | -30% |
| Assets 1 | 52.3 | 162.5 | 236 | 246.1 | 267.9 | 254.5 |
| Book Value Per Share 2 | -287.0 | 70.00 | 57.50 | 47.40 | 47.40 | 28.20 |
| Cash Flow per Share 2 | 350.0 | 28.00 | 26.50 | 19.20 | 36.10 | 15.30 |
| Capex 1 | 2.2 | 7.67 | 3.06 | 0.4 | 1.26 | 0.31 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/24/18 | 3/19/19 | 3/3/20 | 3/3/21 | 3/8/22 | 3/23/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- MGTA Stock
- Financials Magenta Therapeutics
